FDA told me this morning a decision will not apparently be forthcoming in near future. I think Joe knows that and will probably focus on execution. If a buyout occurs next month investors will probably not see the full return in share price. While retail investors appear headed for the exits, we'll probably see a deal in the low 20's. It could have been in the mid to upper 20's if FDA had their #$%$ together. Shorts will probably manipulate this for the next few days and #$%$ posters will be in full force.
Yea, I hope that things get better for this company. Ideally we start seeing uptake in Q1 after the drug is released and this share price will be a distant memory, and we'll be seeing 20 pps on strength of the drug and marketing alone.